Home > Insider Trading > Filing (0001801385-24-000009)

Filing Details

Accession Number:: 0001801385-24-000009
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-03-01 20:16:38
Reporting Period:: 2024-02-28

Accepted Time:: 2024-03-01 20:16:38
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1711279	Krystal Biotech Inc.	KRYS	Biological Products, (No Disgnostic Substances) (2836)	821080209

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1801385	Kathryn Romano	C/O Krystal Biotech, Inc. 2100 Wharton Street, Suite 701 Pittsburgh PA 15203	Chief Accounting Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-02-28	523	$63.55	13,459	No	4	M	Direct
Common Stock	Disposition	2024-02-28	523	$163.13	12,936	No	4	S	Direct
Common Stock	Acquisiton	2024-02-28	744	$63.55	13,680	No	4	M	Direct
Common Stock	Disposition	2024-02-28	744	$164.60	12,936	No	4	S	Direct
Common Stock	Acquisiton	2024-02-28	130	$63.55	13,066	No	4	M	Direct
Common Stock	Disposition	2024-02-28	130	$165.22	12,936	No	4	S	Direct
Common Stock	Acquisiton	2024-02-28	100	$63.55	13,036	No	4	M	Direct
Common Stock	Disposition	2024-02-28	100	$166.22	12,936	No	4	S	Direct
Common Stock	Acquisiton	2024-02-28	700	$63.55	13,636	No	4	M	Direct
Common Stock	Disposition	2024-02-28	700	$168.91	12,936	No	4	S	Direct
Common Stock	Acquisiton	2024-02-28	203	$63.55	13,139	No	4	M	Direct
Common Stock	Disposition	2024-02-28	203	$169.47	12,936	No	4	S	Direct
Common Stock	Acquisiton	2024-02-28	100	$63.55	13,036	No	4	M	Direct
Common Stock	Disposition	2024-02-28	100	$171.45	12,936	No	4	S	Direct
Common Stock	Acquisiton	2024-02-28	637	$63.55	13,573	No	4	M	Direct
Common Stock	Disposition	2024-02-28	637	$162.73	12,936	No	4	S	Direct
Common Stock	Acquisiton	2024-02-28	786	$63.55	13,722	No	4	M	Direct
Common Stock	Disposition	2024-02-28	786	$163.49	12,936	No	4	S	Direct
Common Stock	Acquisiton	2024-02-28	1,600	$63.55	14,536	No	4	M	Direct
Common Stock	Disposition	2024-02-28	1,600	$164.84	12,936	No	4	S	Direct
Common Stock	Acquisiton	2024-02-28	200	$63.55	13,136	No	4	M	Direct
Common Stock	Disposition	2024-02-28	200	$166.04	12,936	No	4	S	Direct
Common Stock	Acquisiton	2024-02-28	300	$63.55	13,236	No	4	M	Direct
Common Stock	Disposition	2024-02-28	300	$167.85	12,936	No	4	S	Direct
Common Stock	Acquisiton	2024-02-28	1,133	$63.55	14,069	No	4	M	Direct
Common Stock	Disposition	2024-02-28	1,133	$169.10	12,936	No	4	S	Direct
Common Stock	Acquisiton	2024-02-28	210	$63.55	13,146	No	4	M	Direct
Common Stock	Disposition	2024-02-28	210	$169.75	12,936	No	4	S	Direct
Common Stock	Acquisiton	2024-02-28	134	$63.55	13,070	No	4	M	Direct
Common Stock	Disposition	2024-02-28	134	$171.66	12,936	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2024-02-28	2,500	$0.00	2,500	$63.55
Common Stock	Stock Option (Right to Buy)	Disposition	2024-02-28	5,000	$0.00	5,000	$63.55

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
35,000		2032-02-28	No	4	M	Direct
30,000		2032-02-28	No	4	M	Direct

Footnotes

The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $140.00 per share.
The transaction was executed in multiple trades ranging from $162.825 to $163.820. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provideupon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $164.030 to $164.960. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $165.050 to $165.270. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $168.275 to $169.190. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $169.345 to $170.000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $145.00 per share.
The transaction was executed in multiple trades ranging from $162.115 to $163.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $163.120 to $164.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $164.360 to $165.270. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $165.980 to $166.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $167.540 to $168.010. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $168.680 to $169.500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $169.690 to $169.970. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $171.460 to $172.230. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
50,000 options were granted that vest in four equal annual installments with the first installment vesting on February 28, 2023.